Trump says he will cut fentanyl tariff on Chinese goods and expects ‘great deal’ with Xi – business live | Business


Key events

GSK boss says UK will struggle to be a ‘life sciences superpower’ without pricing reform

As ministers are drawing up proposals to increase the amount the NHS spends on new medicines, potentially by up to 25%, with an announcement expected as soon as the end of this week, GSK boss Emma Walmsley said she was “hopeful and ambitious” that the standoff with the pharma industry can be resolved.

Without pricing reform, the UK will struggle to be a life sciences superpower, she warned. She told reporters:

We are great supporters of the life sciences industrial strategy in the UK. And I’ve been very consistent on our view that it’s key to execute against that in terms of the opportunity for clinical trials and the opportunity for having translational facilities, all of the work that can be done with the data, but it is absolutely key that we have a competitive, commercial environment that recognises the value of innovation.

Obviously we’re engaging, watching, contributing as we can. And, I would say: hopeful and ambitious.

She added:

What everyone is putting the energy into, hopefully resolving, is how we make sure this country creates the right commercial environment. And without that, I think it’s going to be very difficult to be able to be a leading life sciences superpower… and without that, we are not going to secure something else we all want, which is patient access to innovation. You have to remember that the cost of drugs as a share of the total cost of health care is less than 10% in this country.

Donald Trump has put pressure on pharmaceutical companies to lower their drug prices in the US and sell directly to American patients – or face trade tariffs. (Historically, drug prices in the US have been much higher elsewhere, partly because of a complicated system involving middlemen.) In response, Pfizer and AstraZeneca have done deals with the US government in recent weeks.

Asked whether GSK is going to do a pricing deal with the Trump administration, Walmsley said GSK is “engaging very constructively” with the US government.

We absolutely agree we should be working towards constructive reform in the US system that we want to have affordable, accessible drugs in a sustainable way.

GSK is investing $30bn in US manufacturing and research, but has also affirmed its commitment to the UK. Its bigger UK rival AstraZeneca has paused a planned £200m investment at a Cambridge research site.

Share

Updated at 



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *